Gapping down
In reaction to disappointing earnings/guidance: SRPT -49.7% (also announces FDA Considers NDA Filing for Eteplirsen Premature in Light of Recent Competitive Drug Failure and Recent DMD Natural History Data; FDA Questions Dystrophin as a Biomarker Due to Failed Studies of Other Investigational Drugs for DMD, downgraded to Underweight from Overweight at Piper Jaffray ), HSOL -11.1%, HOLX -10.5%, DGLY -9.2%, BIOL -8.6%, RAX -8.5%, YGE -7.8%, CRAY -6.8%, (light volume), DNDN -5.2%, LEE -5.2%, (reports continued digial growth, achieves plan of reorganization two years early ), DF -4.1%, LXRX -3.9%, (light volume), NTI -3.2%, ESE -2.5%, GSVC -2.4%, NWSA -2.1%, NWS -2.1%, VIPS -0.6%, BID -0.6%.
Financial related names showing weakness: RBS -2.8% (downgraded to Neutral from Buy at Goldman), NBG -2.6%, BCS -1.9%, LYG -1.4%, HBC -1.3%, SAN -0.5%.
Metals/mining stocks trading lower: GOLD -2.4% (downgraded to Sector Perform from Outperform at RBC ), AU -1.8%, GFI -1.8%, MT -1.5%, BHP -1.1%, BBL -1.1%, GLD -0.3%, .
Select oil/gas related names showing early weakness: SDRL -1.8%, STO -1.7%, BP -0.2%.
Solar names lower: SOL -7.1% JKS -6.6% JASO -2.9%, SUNE -1.8%
Other news: BAH -3.1% ( announces secondary offering of 10 mln shares of common stock by affiliate of the Carlyle Group), TMUS -2.6% (announces 66.15 mln share public offering of common stock), APTS -2.6% ( announces proposed public offering of ~3.226 mln shares of common stock), TTM -2.2%, NOK -1.8% (still checking), BUD -1.5% (still checking), QUIK -1.4% (intends to offer newly issued shares of common stock in an underwritten public offering), RCL -1.3% (still checking), ALSN -0.8% ( announces sale of 15 mln shares of common stock by selling stockholders), EBAY -0.6% (eBay lower following ChannelAdvisor Same Store Sales update).
Analyst comments: GSK -1.9% (downgraded to Hold from Buy at Panmure), VECO -1.3% (resumed with a Sell at Canaccord Genuity), FDX -0.5% ( downgraded to Market Perform at Cowen), INTC -0.3% (attributed to analyst downgrade)